Post-Menopausal Osteoporosis Pipeline Assets Segmented By Stage, Product Type, Route of Administration, and Molecule Type

March 10 14:50 2023
Post-Menopausal Osteoporosis Pipeline Assets Segmented By Stage, Product Type, Route of Administration, and Molecule Type

DelveInsight’s, “Postmenopausal Osteoporosis Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in the Postmenopausal Osteoporosis pipeline landscape. It covers the Post-Menopausal Osteoporosis pipeline drug profiles, including Post-Menopausal Osteoporosis clinical trials and nonclinical stage products. It also covers the Post-Menopausal Osteoporosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Post-Menopausal Osteoporosis Emerging drugs, the Post-Menopausal Osteoporosis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Post-Menopausal Osteoporosis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Post-Menopausal Osteoporosis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Post-Menopausal Osteoporosis clinical trials studies, Post-Menopausal Osteoporosis NDA approvals (if any), and product development activities comprising the technology, Post-Menopausal Osteoporosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Post-Menopausal Osteoporosis Pipeline Insight Report

 

  • DelveInsight’s Post-Menopausal Osteoporosis pipeline report depicts a robust space with 18+ active players working to develop 18+ pipeline therapies for Post-Menopausal Osteoporosis treatment.

 

  • The leading Post-Menopausal Osteoporosis Companies includes Teva Pharmaceutical, Transcenta Holding, Shanghai Biomabs Pharmaceutical, HEXAL, Samsung Bioepis, Shenzhen Salubris Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd, Celltrion, Mabwell (Shanghai) Bioscience Co., Ltd., PhytoHealth, Luye Pharma, Sandoz International GmbH, Addpharma, and others.

 

  • Promising Post-Menopausal Osteoporosis Pipeline Therapies includes TVB-009, SB16, ibandronate [Bonviva/Boniva], Risedronate, RGB-14-P, Romosozumab, Alendronate, and others.
  • The Post-Menopausal Osteoporosis companies and academics are working to assess challenges and seek opportunities that could influence Postmenopausal Osteoporosis R&D. The Post-Menopausal Osteoporosis pipeline therapies under development are focused on novel approaches to treat/improve Postmenopausal Osteoporosis.

 

Request a sample and discover the recent breakthroughs happening in the Post-Menopausal Osteoporosis Pipeline landscape @ Post-Menopausal Osteoporosis Pipeline Outlook Report

 

Post-Menopausal Osteoporosis Overview

Osteoporosis is a metabolic bone disorder that is characterized by low bone mass and micro-architectural deterioration of bone tissue. Fractures of the proximal femur, the vertebrae and the distal radius are the most frequent osteoporotic fractures, although most fractures in the elderly are probably at least partly related to bone fragility. The incidence of fractures varies greatly by country, but on average up to 50% of women >50 years of age are at risk of fractures. Fractures severely affect the quality of life of an individual and are becoming a major public health problem owing to the ageing population.

 

Post-Menopausal Osteoporosis Emerging Drugs Profile

 

  • TVB-009: Teva Pharmaceutical

TVB-009 is a Denosumab biosimilar being developed by Teva Pharmaceutical for the treatment of patients with Postmenopausal osteoporosis. TVB-009 is a RANK ligand inhibitor and is currently in Phase III stage of clinical trial evaluation to treat Postmenopausal osteoporosis. 

 

  • SB16: Samsung Bioepis

SB16 is a Denosumab biosimilar being developed by Samsung Bioepis to treat Postmenopausal osteoporosis. The company is conducting a Phase III clinical trial to compare the efficacy and safety of SB16 with the original drug on 432 post-menopausal osteoporosis patients in six countries.

 

For further information, refer to the detailed Post-Menopausal Osteoporosis Drugs Launch, Post-Menopausal Osteoporosis Developmental Activities, and Post-Menopausal Osteoporosis News, click here for Post-Menopausal Osteoporosis Ongoing Clinical Trial Analysis

 

Post-Menopausal Osteoporosis Pipeline Therapeutics Assessment

There are approx. 18+ key companies which are developing the therapies for Postmenopausal Osteoporosis. The companies which have their Postmenopausal Osteoporosis drug candidates in the most advanced stage, i.e. phase III include, Teva Pharmaceutical.

 

Post-Menopausal Osteoporosis Pipeline: Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Find out more about the Post-Menopausal Osteoporosis Pipeline Segmentation, Therapeutics Assessment, and Post-Menopausal Osteoporosis Emerging Drugs @ Post-Menopausal Osteoporosis Treatment Landscape

 

Scope of the Post-Menopausal Osteoporosis Pipeline Report

 

  • Coverage- Global

 

  • Post-Menopausal Osteoporosis Companies- Teva Pharmaceutical, Transcenta Holding, Shanghai Biomabs Pharmaceutical, HEXAL, Samsung Bioepis, Shenzhen Salubris Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd, Celltrion, Mabwell (Shanghai) Bioscience Co., Ltd., PhytoHealth, Luye Pharma, Sandoz International GmbH, Addpharma, and others.

 

  • Post-Menopausal Osteoporosis Pipeline Therapies- TVB-009, SB16, ibandronate [Bonviva/Boniva], Risedronate, RGB-14-P, Romosozumab, Alendronate, and others.

 

  • Post-Menopausal Osteoporosis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Post-Menopausal Osteoporosis Pipeline Companies and Therapies, click here @ Post-Menopausal Osteoporosis Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Postmenopausal osteoporosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Postmenopausal osteoporosis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. TVB-009: Teva Pharmaceutical
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. TST-002: Transcenta Holding
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Postmenopausal osteoporosis Key Companies
  21. Postmenopausal osteoporosis Key Products
  22. Postmenopausal osteoporosis- Unmet Needs
  23. Postmenopausal osteoporosis- Market Drivers and Barriers
  24. Postmenopausal osteoporosis- Future Perspectives and Conclusion
  25. Postmenopausal osteoporosis Analyst Views
  26. Postmenopausal osteoporosis Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Post-Menopausal Osteoporosis Mergers and acquisitions, Post-Menopausal Osteoporosis Licensing Activities @ Post-Menopausal Osteoporosis Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

  Categories: